Cobicistat is a pharmacokinetic enhancer used in combination with certain antiretroviral drugs to boost their effectiveness in the treatment of HIV-1 infection. It has no antiviral activity of its own but acts as a potent inhibitor of cytochrome P450 3A (CYP3A) enzymes, thereby increasing the plasma concentrations of co-administered drugs like atazanavir or elvitegravir.
Cobicistat improves the dosing convenience and therapeutic efficacy of combination HIV therapies and is often included in fixed-dose combinations (e.g., Stribild®, Genvoya®).
Indications include (always in combination):
∙ HIV-1 infection in adults and pediatric patients
∙ Used to enhance the pharmacokinetics of protease inhibitors or integrase strand transfer inhibitors
Impurities in cobicistat can originate from its complex chemical synthesis and may also result from degradation during storage or formulation. Due to its use in chronic HIV therapy, impurity levels must comply with ICH Q3A/B and pharmacopeial (USP/EP) limits.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Cobicistat is used as a pharmacokinetic booster in HIV treatment. It enhances the effectiveness of other antiretroviral drugs by inhibiting the CYP3A enzymes that would normally break them down.
No. It does not directly attack the virus but supports other drugs by increasing their blood levels.
Caution is advised. While cobicistat affects creatinine levels without harming renal function directly, dose adjustments may be needed for the co-administered antiretrovirals.
It is generally stable under controlled conditions but can degrade with exposure to light, heat, or moisture. Proper storage in a cool, dry place is essential.
